A recent study published in the journal Diabetes Therapy discusses the results of the PIONEER REAL study conducted in the Netherlands, which evaluated the efficacy of oral semaglutide in managing type 2 diabetes and supporting weight loss. Study: Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study. Image Credit: Davor Geber / Shutterstock.
com In 2021, about 500 million people were estimated to be living with type 2 diabetes throughout the world. The prevalence of type 2 diabetes is expected to continue to rise, with researchers estimating that approximately 700 million will be diagnosed with this condition by 2045. In the Netherlands, an estimated 1.
1 million people were living with diabetes in 2021, over 90% of whom were diagnosed with type 2 diabetes . With such a high prevalence, type 2 diabetes is associated with an annual cost of €1.3 billion in the Netherlands.
The Netherlands Diabetes Federation recommends a stepwise introduction of diabetes treatments based on glycated hemoglobin (HbA1c) levels. Typically, treatment is initiated sequentially with metformin and sulphonylureas, followed by the incorporation of insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), or dipeptidyl peptidase-4 (DPP-4) inhibitors. Semaglutide is a GLP-1 analog currently available as daily subcutaneous and oral formulations.
In addition to diet and exercise, semaglutide has been shown to effe.